

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

Market Report | 2025-05-30 | 560 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The biomarkers market is expected to reach USD 104.15 billion in 2030 from USD 62.39 billion in 2025, at a CAGR of 10.8% during the forecast period. The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

"The predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market in 2024."

The market by type is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. This large share is supported by the ability of predictive biomarker-based offerings to guide treatment decisions and improve clinical outcomes by identifying patients most likely to benefit from a particular therapeutic intervention, which is especially valuable in oncology, autoimmune disorders, and infectious diseases. Moreover, the growing number of companion diagnostic approvals linked to predictive biomarkers further reinforced their adoption across healthcare settings. For instance, Roche's PATHWAY anti-HER2/neu (4B5) test identifies HER2-low breast cancer patients eligible for trastuzumab deruxtecan (ENHERTU), which received a label expansion in January 2025 to identify HER2-ultralow patients in HR-positive, HER2-negative metastatic breast cancer.

"Immunoassays held the largest share in the biomarker technologies market in 2024."

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2024, immunoassays held the largest market share in the biomarkers market due to their high specificity and ability to detect various biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases. Scalability and automation capabilities further support high-throughput testing, meeting the rising demand for precision diagnostics. Major companies are actively advancing immunoassay platforms to enhance their diagnostic offerings. For instance, Roche offers the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott continues to expand its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring.

"The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period."

The Asia Pacific is projected to register the highest growth rate in the biomarkers market during the forecast period. Key drivers of this growth include a large patient population undergoing advanced medical testing and supportive healthcare policies to improve cancer care. Additionally, increased research activity by pharmaceutical and biotechnology companies to develop novel drug therapies is expected to accelerate market expansion. As investment in drug development continues to rise across the region, the demand for biomarkers that support drug discovery and development efforts is growing steadily.

The primary interviews conducted for this report can be categorized as follows:

-□By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%

-□By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%

-□By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), and Laboratory Corporation of America Holdings (US) are some of the key players in the biomarkers market.

The study includes an in-depth competitive analysis of these key players in the biomarkers market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the biomarkers market by offering [consumables (assay kits, columns & filters, reagents & chemicals), services, and software], type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology [immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies], disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (increasing use of biomarkers in drug discovery & development, growing importance of companion diagnostics, rising prevalence of cancer, developments of biomarkers for rare diseases, increasing funds and grants for biomarker research, advancement in omics technologies), restraints (high capital investments and extensive timelines for biomarker

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

development, disease complexity, and heterogeneity), opportunities (growing preference for personalized medicine and precision oncology, enhanced collaboration among healthcare providers and key industry players, high growth potential of emerging economies), and challenges (issues associated with quantification and validation of biomarkers, complexities associated with data set integration, technical issues related to sample collection and storage) influencing the growth of the market.

-□Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market

-□Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMERIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), and Quanterix (US), among others, in the biomarkers market.

Table of Contents:

1	INTRODUCTION	43
1.1	STUDY OBJECTIVES	43
1.2	MARKET DEFINITION	44
1.2.1	INCLUSIONS & EXCLUSIONS	44
1.3	STUDY SCOPE	46
1.3.1	STUDY SCOPE	46
1.4	YEARS CONSIDERED	47
1.5	CURRENCY CONSIDERED	47
1.6	STAKEHOLDERS	47
1.7	SUMMARY OF CHANGES	48
2	RESEARCH METHODOLOGY	49
2.1	RESEARCH DATA	49
2.1.1	SECONDARY DATA	50
2.1.2	PRIMARY DATA	51
2.2	MARKET ESTIMATION METHODOLOGY	52
2.2.1	INSIGHTS OF PRIMARY EXPERTS	55
2.2.2	TOP-DOWN APPROACH	55
2.3	MARKET GROWTH RATE FORECAST	56
2.4	MARKET BREAKDOWN & DATA TRIANGULATION	58
2.5	RESEARCH ASSUMPTIONS	59
2.6	RESEARCH LIMITATIONS	60
2.7	RISK ASSESSMENT	61
3	EXECUTIVE SUMMARY	62
4	PREMIUM INSIGHTS	67
4.1	BIOMARKERS MARKET OVERVIEW	67
4.2	ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING	68
4.3	BIOMARKERS MARKET SHARE, BY END USER, 2024	69
4.4	BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	69
5	MARKET OVERVIEW	70
5.1	INTRODUCTION	70
5.2	MARKET DYNAMICS	70
5.2.1	MARKET DRIVERS	72

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.1.1 Increasing use of biomarkers in drug discovery & development 72
- 5.2.1.2 Growing importance of companion diagnostics 72
- 5.2.1.3 Rising prevalence of cancer 73
- 5.2.1.4 Development of biomarkers for rare diseases 74
- 5.2.1.5 Increasing funds and grants for biomarker research 75
- 5.2.1.6 Advancement in omics technologies 76
- 5.2.2 RESTRAINTS 77
 - 5.2.2.1 High capital investments and extensive timelines for biomarker development 77
 - 5.2.2.2 Disease complexity and heterogeneity 78
- 5.2.3 OPPORTUNITIES 79
 - 5.2.3.1 Growing preference for personalized medicine and precision oncology 79
 - 5.2.3.2 Enhanced collaboration among healthcare providers and key industry players 79
 - 5.2.3.3 High growth potential of emerging economies 80
- 5.2.4 CHALLENGES 81
 - 5.2.4.1 Issues associated with quantification & validation of biomarkers 81
 - 5.2.4.2 Complexities associated with data set integration 82
 - 5.2.4.3 Technical issues related to sample collection and storage 82
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 82
- 5.4 REGULATORY ANALYSIS 83
 - 5.4.1 REGULATORY SCENARIO 83
 - 5.4.1.1 US 83
 - 5.4.1.2 Europe 84
 - 5.4.1.3 Asia Pacific 84
 - 5.4.1.4 Rest of the World 85
 - 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
- 5.5 VALUE CHAIN ANALYSIS 91
- 5.6 TECHNOLOGICAL ANALYSIS 93
 - 5.6.1 KEY TECHNOLOGIES 93
 - 5.6.1.1 Immunoassays 93
 - 5.6.1.1.1 Immunohistochemistry (IHC) 93
 - 5.6.1.1.2 ELISA 94
 - 5.6.1.2 Next-generation Sequencing (NGS) 94
 - 5.6.1.3 Polymerase chain reaction (PCR) 94
 - 5.6.1.4 In situ hybridization 95
 - 5.6.1.5 Microarrays 95
 - 5.6.1.6 Mass Spectrometry 95
 - 5.6.2 COMPLEMENTARY TECHNOLOGIES 96
 - 5.6.2.1 Liquid biopsy 96
 - 5.6.2.2 CRISPR 96
 - 5.6.3 ADJACENT TECHNOLOGIES 96
 - 5.6.3.1 Artificial intelligence (AI) and machine learning (ML) 96
 - 5.6.3.2 Sensors (wearable devices) 96
- 5.7 PRICING ANALYSIS 97
 - 5.7.1 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022-2024 97
 - 5.7.2 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024 98

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.8	PATENT ANALYSIS	99
5.8.1	METHODOLOGY	99
5.8.2	NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2025	99
5.9	ECOSYSTEM ANALYSIS	103
5.10	KEY CONFERENCES & EVENTS, 2025-2026	104
5.11	PORTER'S FIVE FORCES ANALYSIS	105
5.11.1	INTENSITY OF COMPETITIVE RIVALRY	106
5.11.2	BARGAINING POWER OF SUPPLIERS	106
5.11.3	BARGAINING POWER OF BUYERS	107
5.11.4	THREAT OF SUBSTITUTES	107
5.11.5	THREAT OF NEW ENTRANTS	107
5.12	KEY STAKEHOLDERS & BUYING CRITERIA	108
5.12.1	KEY STAKEHOLDERS IN BUYING PROCESS	108
5.12.2	BIOMARKERS MARKET: BUYING CRITERIA	109
5.13	INVESTMENT & FUNDING SCENARIO	110
5.14	TRADE DATA ANALYSIS	111
5.14.1	IMPORT SCENARIO: HS CODE 382200, 2020-2024	112
5.14.2	EXPORT SCENARIO: HS CODE 382200, 2020-2024	113
5.15	IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET	114
5.15.1	INTRODUCTION	114
5.15.2	USE CASES	114
5.15.3	FUTURE OF AI IN BIOMARKER ECOSYSTEM	116
5.16	IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET	116
5.16.1	KEY TARIFF RATES	117
5.16.2	PRICE IMPACT ANALYSIS	118
5.16.3	IMPACT ON COUNTRIES/REGIONS	119
5.16.3.1	US	119
5.16.3.2	Europe	120
5.16.3.3	Asia Pacific	121
5.16.4	IMPACT ON END-USE INDUSTRIES	121
5.16.4.1	Pharmaceutical & biotech companies	122
5.16.4.2	Hospitals & diagnostic laboratories	122
5.16.4.3	Contract research organizations	122
?		
6	BIOMARKERS MARKET, BY OFFERING	123
6.1	INTRODUCTION	124
6.2	CONSUMABLES	124
6.2.1	ASSAY KITS	128
6.2.1.1	Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth	128
6.2.2	REAGENTS & CHEMICALS	132
6.2.2.1	Recurrent usage of reagents & chemicals in drug discovery and development to support demand	132
6.2.3	OTHER CONSUMABLES	136
6.3	SERVICES	139
6.3.1	GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION	139
6.4	SOFTWARE	143
6.4.1	INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH	143
7	BIOMARKERS MARKET, BY TYPE	147

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1	INTRODUCTION	148
7.2	SAFETY BIOMARKERS	148
7.2.1	WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH	148
7.3	EFFICACY BIOMARKERS	152
7.3.1	PREDICTIVE BIOMARKERS	155
7.3.1.1	Rising applications of biomarkers in personalized medicine to drive market	155
7.3.2	SURROGATE BIOMARKERS	159
7.3.2.1	Ability to serve as reliable indicator in place of clinical endpoints to support market growth	159
7.3.3	PHARMACODYNAMIC BIOMARKERS	163
7.3.3.1	Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market	163
7.3.4	PROGNOSTIC BIOMARKERS	167
7.3.4.1	Increasing number of clinical trials to support growth of prognostic biomarkers	167
7.4	VALIDATION BIOMARKERS	170
7.4.1	RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH	170
8	BIOMARKERS MARKET, BY RESEARCH AREA	174
8.1	INTRODUCTION	175
8.2	GENOMICS	175
8.2.1	ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH	175
?		
8.3	PROTEOMICS	179
8.3.1	GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND	179
8.4	METABOLOMICS	183
8.4.1	RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH	183
8.5	OTHER RESEARCH AREAS	186
9	BIOMARKERS MARKET, BY TECHNOLOGY	190
9.1	INTRODUCTION	191
9.2	IMMUNOASSAYS	191
9.2.1	ELISA	195
9.2.1.1	Extensive application of ELISA assays in clinical laboratories to support growth	195
9.2.2	PROTEIN MICROARRAYS	199
9.2.2.1	Quick and cost-effective nature of technology to support growth	199
9.2.3	WESTERN BLOT	203
9.2.3.1	Increasing investments in proteomics research to drive market	203
9.3	NEXT-GENERATION SEQUENCING (NGS)	206
9.3.1	TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH	206
9.4	POLYMERASE CHAIN REACTION (PCR)	210
9.4.1	RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET	210
9.5	MASS SPECTROMETRY	214
9.5.1	INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH	214
9.6	CHROMATOGRAPHY	217
9.6.1	GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH	217
9.7	OTHER TECHNOLOGIES	221
10	BIOMARKERS MARKET, BY DISEASE INDICATION	225
10.1	INTRODUCTION	226
10.2	CANCER	226
10.2.1	INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET	226
10.3	INFECTIOUS DISEASES	231

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.1 INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND 231
- 10.4 IMMUNOLOGICAL DISORDERS 235
 - 10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET 235
- 10.5 NEUROLOGICAL DISORDERS 239
 - 10.5.1 WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH 239
- 10.6 CARDIOVASCULAR DISORDERS 243
 - 10.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS 243
- 10.7 OTHER DISEASE INDICATIONS 247
- 11 BIOMARKERS MARKET, BY APPLICATION 251
 - 11.1 INTRODUCTION 252
 - 11.2 CLINICAL DIAGNOSTICS 252
 - 11.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND 252
 - 11.3 DRUG DISCOVERY & DEVELOPMENT 256
 - 11.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH 256
 - 11.4 PERSONALIZED MEDICINE 260
 - 11.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND 260
 - 11.5 CLINICAL RESEARCH 264
 - 11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET 264
 - 11.6 OTHER APPLICATIONS 268
- 12 BIOMARKERS MARKET, BY END USER 272
 - 12.1 INTRODUCTION 273
 - 12.2 PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES 273
 - 12.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH 273
 - 12.3 HOSPITALS & DIAGNOSTIC LABORATORIES 278
 - 12.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH 278
 - 12.4 ACADEMIC & RESEARCH INSTITUTES 282
 - 12.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET 282
 - 12.5 OTHER END USERS 285
- 13 BIOMARKERS MARKET, BY REGION 289
 - 13.1 INTRODUCTION 290
 - 13.2 NORTH AMERICA 290
 - 13.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA 291
 - 13.2.2 US 297
 - 13.2.2.1 Rising focus on biopharma research to support growth 297
 - 13.2.3 CANADA 302
 - 13.2.3.1 Increasing incidence of cancer to drive biomarkers market growth 302
 - 13.3 EUROPE 307
 - 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 307
 - 13.3.2 GERMANY 313
 - 13.3.2.1 Growth in biopharmaceutical R&D activities to propel growth 313
 - 13.3.3 UK 318
 - 13.3.3.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers 318
 - 13.3.4 FRANCE 323
 - 13.3.4.1 Increasing government investment for proteomics & genomics research to drive growth 323
 - 13.3.5 ITALY 328

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.3.5.1 Increasing developments in life science research to fuel growth 328
- 13.3.6 SPAIN 332
- 13.3.6.1 R&D initiatives for personalized medicine to support market growth 332
- 13.3.7 REST OF EUROPE 337
- 13.4 ASIA PACIFIC 342
- 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 342
- 13.4.2 CHINA 349
- 13.4.2.1 Rising incidence of CVD to propel market 349
- 13.4.3 JAPAN 354
- 13.4.3.1 Strong regulatory guidelines for drug discovery & development to support market growth 354
- 13.4.4 INDIA 359
- 13.4.4.1 Favorable scenario for FDI and increasing number of clinical trials to propel market 359
- 13.4.5 SOUTH KOREA 364
- 13.4.5.1 Increasing innovations in NGS technologies to support market growth 364
- 13.4.6 AUSTRALIA 369
- 13.4.6.1 Increasing demand for diagnostic solutions to propel market 369
- 13.4.7 REST OF ASIA PACIFIC 373
- 13.5 LATIN AMERICA 378
- 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 378
- 13.5.2 BRAZIL 384
- 13.5.2.1 Increased government investments in pharmaceutical R&D to drive market 384
- 13.5.3 MEXICO 388
- 13.5.3.1 Rising demand for chronic disease treatment to support market growth 388
- 13.5.4 REST OF LATIN AMERICA 393
- 13.6 MIDDLE EAST 398
- 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 398
- 13.6.2 GCC COUNTRIES 403
- 13.6.3 SAUDI ARABIA 407
- 13.6.3.1 Growing healthcare expenditure to boost market growth 407
- 13.6.4 UAE 412
- 13.6.4.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth 412
- ?
- 13.6.5 REST OF GCC COUNTRIES 416
- 13.6.5.1 Other GCC countries include Bahrain, Kuwait, Oman, and Qatar. 416
- 13.6.6 REST OF MIDDLE EAST 421
- 13.6.6.1 The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq. 421
- 13.7 AFRICA 426
- 13.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 426
- 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 426
- 14 COMPETITIVE LANDSCAPE 432
- 14.1 INTRODUCTION 432
- 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 432
- 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET 432
- 14.3 REVENUE ANALYSIS, 2022-2024 436
- 14.4 MARKET SHARE ANALYSIS, 2024 438
- 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 441
- 14.5.1 STARS 442

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.5.2 EMERGING LEADERS 442
- 14.5.3 PERVASIVE PLAYERS 442
- 14.5.4 PARTICIPANTS 442
- 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 444
 - 14.5.5.1 Company footprint 444
 - 14.5.5.2 Region footprint 445
 - 14.5.5.3 Offering footprint 446
 - 14.5.5.4 Technology footprint 448
 - 14.5.5.5 Application footprint 450
- 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 452
 - 14.6.1 PROGRESSIVE COMPANIES 452
 - 14.6.2 RESPONSIVE COMPANIES 452
 - 14.6.3 DYNAMIC COMPANIES 452
 - 14.6.4 STARTING BLOCKS 452
 - 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 454
 - 14.6.5.1 Detailed list of key startups/SMEs 454
 - 14.6.5.2 Competitive benchmarking of key startups/SMEs 456
- 14.7 COMPANY VALUATION & FINANCIAL METRICS 457
 - 14.7.1 VALUATION OF KEY PLAYERS 457
 - 14.7.2 FINANCIAL METRICS OF KEY PLAYERS 457
- 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 458
 - 14.8.1 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS 458
- ?
- 14.9 COMPETITIVE SCENARIO 459
 - 14.9.1 PRODUCT LAUNCHES & APPROVALS 459
 - 14.9.2 DEALS 460
 - 14.9.3 EXPANSIONS 461
- 15 COMPANY PROFILES 462
 - 15.1 KEY PLAYERS 462
 - 15.1.1 THERMO FISHER SCIENTIFIC INC. 462
 - 15.1.1.1 Business overview 462
 - 15.1.1.2 Products & services offered 463
 - 15.1.1.3 Recent developments 469
 - 15.1.1.3.1 Product launches & approvals 469
 - 15.1.1.3.2 Deals 470
 - 15.1.1.3.3 Expansions 471
 - 15.1.1.4 MnM view 472
 - 15.1.1.4.1 Right to win 472
 - 15.1.1.4.2 Strategic choices 472
 - 15.1.1.4.3 Weaknesses & competitive threats 472
 - 15.1.2 MERCK KGAA 473
 - 15.1.2.1 Business overview 473
 - 15.1.2.2 Products & services offered 474
 - 15.1.2.3 Recent developments 477
 - 15.1.2.3.1 Deals 477
 - 15.1.2.3.2 Expansions 478
 - 15.1.2.4 MnM view 478

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.2.4.1 Right to win 478
- 15.1.2.4.2 Strategic choices 478
- 15.1.2.4.3 Weaknesses & competitive threats 478
- 15.1.3 F. HOFFMANN-LA ROCHE LTD. 479
 - 15.1.3.1 Business overview 479
 - 15.1.3.2 Products & services offered 480
 - 15.1.3.3 Recent developments 482
 - 15.1.3.3.1 Product launches & approvals 482
 - 15.1.3.3.2 Deals 485
- 15.1.4 QIAGEN 486
 - 15.1.4.1 Business overview 486
 - 15.1.4.2 Products & services offered 487
 - 15.1.4.3 Recent developments 489
 - 15.1.4.3.1 Product launches & approvals 489
 - 15.1.4.3.2 Deals 490
 - 15.1.4.3.3 Expansions 491
- ?
- 15.1.5 ABBOTT 492
 - 15.1.5.1 Business overview 492
 - 15.1.5.2 Products & services offered 493
 - 15.1.5.3 Recent developments 495
 - 15.1.5.3.1 Product launches & approvals 495
 - 15.1.5.3.2 Deals 495
- 15.1.6 AGILENT TECHNOLOGIES, INC. 496
 - 15.1.6.1 Business overview 496
 - 15.1.6.2 Products & services offered 497
 - 15.1.6.3 Recent developments 498
 - 15.1.6.3.1 Product launches & approvals 498
 - 15.1.6.3.2 Deals 499
- 15.1.7 REVVITY INC. 501
 - 15.1.7.1 Business overview 501
 - 15.1.7.2 Products & services offered 502
- 15.1.8 CHARLES RIVER LABORATORIES 504
 - 15.1.8.1 Business overview 504
 - 15.1.8.2 Products & services offered 505
 - 15.1.8.3 Recent developments 506
 - 15.1.8.3.1 Deals 506
- 15.1.9 BIO-RAD LABORATORIES, INC. 507
 - 15.1.9.1 Business overview 507
 - 15.1.9.2 Products & services offered 508
 - 15.1.9.3 Recent developments 510
 - 15.1.9.3.1 Product launches 510
 - 15.1.9.3.2 Deals 510
- 15.1.10 EUROFINS SCIENTIFIC 511
 - 15.1.10.1 Business overview 511
 - 15.1.10.2 Products & services offered 512
 - 15.1.10.3 Recent developments 513

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.10.3.1 Deals 513
- 15.1.11 BIOMERIEUX 514
 - 15.1.11.1 Business overview 514
 - 15.1.11.2 Products & services offered 515
 - 15.1.11.3 Recent developments 516
 - 15.1.11.3.1 Product launches & approvals 516
 - 15.1.11.3.2 Deals 516
- 15.1.12 ILLUMINA, INC. 517
 - 15.1.12.1 Business overview 517
 - 15.1.12.2 Products & services offered 519
 - 15.1.12.3 Recent developments 519
 - 15.1.12.3.1 Product launches & approvals 519
 - 15.1.12.3.2 Deals 520
- 15.1.13 SR CORPORATION 521
 - 15.1.13.1 Business overview 521
 - 15.1.13.2 Products & services offered 522
 - 15.1.13.3 Recent developments 523
 - 15.1.13.3.1 Deals 523
- 15.1.14 GUARDANT HEALTH 524
 - 15.1.14.1 Business overview 524
 - 15.1.14.2 Products & services offered 526
 - 15.1.14.3 Recent developments 526
 - 15.1.14.3.1 Product launches & approvals 526
 - 15.1.14.3.2 Deals 527
- 15.1.15 LABCORP 529
 - 15.1.15.1 Business overview 529
 - 15.1.15.2 Products & services offered 530
 - 15.1.15.3 Recent developments 531
 - 15.1.15.3.1 Product launches 531
- 15.1.16 QUANTERIX 532
 - 15.1.16.1 Business overview 532
 - 15.1.16.2 Products & services offered 533
 - 15.1.16.3 Recent developments 534
 - 15.1.16.3.1 Product launches 534
 - 15.1.16.3.2 Deals 534
- 15.1.17 MESO SCALE DIAGNOSTICS, LLC 535
 - 15.1.17.1 Business overview 535
 - 15.1.17.2 Products & services offered 535
- 15.2 OTHER PLAYERS 537
 - 15.2.1 CELERION 537
 - 15.2.2 STANDARD BIOTOOLS 538
 - 15.2.3 SEBIA 539
 - 15.2.4 BIOAGILYTIX LABS 540
 - 15.2.5 STRESSMARQ BIOSCIENCES INC. 541
 - 15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC 542
 - 15.2.7 SIGNOSIS 543
 - 15.2.8 SERIMMUNE 544

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.2.9 THERAINDX LIFESCIENCES PVT. LTD. 544

15.2.10 SYNEXA LIFE SCIENCES BV 545

15.2.11 DIATECH PHARMACOGENETICS 546

15.2.12 SINGULEX, INC. 547

15.2.13 R-BIOPHARM AG 548

?

16 APPENDIX 549

16.1 DISCUSSION GUIDE 549

16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 555

16.3 CUSTOMIZATION OPTIONS 557

16.4 RELATED REPORTS 558

16.5 AUTHOR DETAILS 559

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

Market Report | 2025-05-30 | 560 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-06-09

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com